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Abstract.  The interaction of cells with extracellular 
matrix components such as fibronectin, vitronectin, 
and type I collagen has been shown to be mediated 
through a  family of cell-surface receptors that 
specifically recognize an arginine-glycine-aspartic acid 
(RGD) amino acid sequence within each protein.  Syn- 
thetic peptides containing the RGD sequence can in- 
hibit these receptor-ligand interactions. Here, we use 
novel RGD-containing synthetic peptides with different 
inhibition properties to investigate the role of the vari- 
ous RGD receptors in tumor cell invasion. The RGD- 
containing peptides used include peptides that inhibit 
the attachment of cells to fibronectin and vitronectin, a 
peptide that inhibits attachment to fibronectin but not 
to vitronectin, a  cyclic peptide with the opposite 
specificity, and a peptide,  GRGDTP, that inhibits at- 
tachment to type I collagen in addition to inhibiting 
attachment to fibronectin and vitronectin. The penetra- 
tion of two human melanoma cell lines and a  glioblas- 
toma cell line through the human amniotic basement 
membrane and its underlying stroma was inhibited by 
all of the RGD-containing peptides except for the one 
that inhibits only the vitronectin attachment. Various 
control peptides lacking RGD showed essentially no 
inhibition. This inhibitory effect on cell invasion was 
dose-dependent and nontoxic. A  hexapeptide, GRGDTP, 
that inhibits the attachment of cells to type I collagen 
in addition to inhibiting fibronectin- and vitronectin- 
mediated attachment was more inhibitory than those 
RGD peptides that inhibit only fibronectin and 
vitronectin attachment. Analysis of the location of 
these cells that were prevented from invading indicated 
that they attached to the amniotic basement membrane 
but did not proceed further into the tissue. These 
results suggest that interactions between RGD-contain- 
ing extracellular matrix adhesion proteins and cells are 
necessary for cell invasion through tissues and that 
fibronectin and type I collagen are important for this 
process. 
T 
HE metastatic process is comprised of  a complex series 
of events the details of which are largely unknown. For 
a tumor cell to be metastatic, it must be capable of at- 
taching to the extracellular matrices that separate tissues and 
must penetrate such matrices (reviews,  Fidler et al.,  1978; 
Liotta et al.,  1983; Nicolson, 1984). Extracellular matrices 
are composed of macromolecules that include fibronectin, 
laminin, collagens, and proteoglycans. These molecules can 
promote cell adhesion and migration (reviews,  Hynes and 
Yamada,  1982; Ruoslahti and Pierschbacher,  1987) and are 
believed to play a role in embryonic cell migrations (Bron- 
ner-Fraser, 1986; Duband and Thiery, 1982; Erickson et al., 
1980; Goodman and Newgreen,  1985) and tumor cell inva- 
sion (Lacovara et al.,  1984; Liotta et al.,  1986; McCarthy 
and Furcht,  1984; Mignatti et al.,  1986; Ruoslahti,  1984). 
The interaction of cells with the extracellular matrix is medi- 
ated by cell surface receptors. 
Receptors for fibronectin, type I collagen, vitronectin, and 
laminin have been identified (reviews,  Liotta et al.,  1986; 
Ruoslahti and  Pierschbacher,  1987). Of these proteins  at 
least fibronectin, type I collagen, and vitronectin have the 
three amino-acid sequence, arginine-glycine-aspartic acid 
(RGD)  as  the core  structure recognized by the  receptors 
(Pierschbacher and Ruoslahti,  1984a,b; Ruoslahti and Piersch- 
bacher,  1987). Synthetic peptides containing the RGD se- 
quence are capable of competing with each of these adhesion 
proteins for its receptor thereby inhibiting cell attachment 
and migration of both normal and tumor cells on substrates 
coated with the adhesion proteins (Hayman et al.,  1985a; 
Pierschbacher and Ruoslahti 1984a,b; Yamada and Kennedy, 
1985). Thus, such peptides have become valuable tools for 
the analysis of cell adhesion phenomena. 
In this report,  we have used a  series of novel synthetic 
RGD-containing  peptides  (Pierschbacher  and  Ruoslahti, 
1987)  to  obtain  information  about  tumor  cell  invasion 
through the human amniotic membrane in vitro. We find that 
the migration of several types of tumor cells through the am- 
nion can be inhibited with RGD-containing peptides, thus 
suggesting an important role for the RGD receptors in cell 
migration through tissue matrices. We also find that peptides 
which are selective for the various receptors show different 
degrees of activity, allowing conclusions to be drawn about 
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vasive process. 
Materials and Methods 
Cell Lines 
The cell lines used included two human melanoma cell lines designated 
A375P and A375M,  the derivation and metastatic properties of which have 
been described (Kozlowski et al., 1984). They were obtained from I. J. Fid- 
let, (M. D. Anderson Hospital and Tumor Institute,  Houston, TX). A human 
glioblastoma cell line (RuGli), was obtained from Dr. S. L. Goodman (Max 
Planck Institute, Munich, Federal Republic of Germany) (Goodman and 
Newgreen, 1985). All of the cells were cultured in DME (Gibco, Chagrin 
Falls, OH) supplemented  with 10% heat-inactivated fetal bovine serum (Tis- 
sue Culture Biologicals, Tulare,  CA) and 0.1%  gentamicin (Gibco). 
Cells were removed from culture dishes using 2 mM EDTA in PBS de- 
void of Ca ++ and Mg  ++ for all assays. Cell viability in all assays was deter- 
mined using the Trypan Blue exclusion test. 
Proteins and Synthetic Peptides 
Fibronectin and vitronectin were purified according to published procedures 
(Hayman et al.,  1985b; Ruoslahti et al.,  1982).  Laminin, and types I and 
IV collagen were purchased (Collaborative Research, Bedford, MA). These 
proteins  were  used to  coat  polystyrene dishes as  previously described 
(Ruoslahti et al.,  1982). 
Peptides were synthesized using an Applied Biosystems (Model 430A; 
Foster City, CA) automated peptide synthesizer using the chemistry recom- 
mended by the manufacturer and purified by reverse phase HPLC on a Bio- 
gel TSK SPo5-PW cation exchange column (Bio-Rad Laboratories, Rich- 
mond, CA). A cyclic peptide and the peptides containing D-amino acids 
were the same as described elsewhere (Pierschbacher and Ruoslahti, 1987). 
For the invasion assays, the peptides were dissolved in DME with 2% 
fetal bovine serum, 0.1% gentamicin, and 10 mM Hepes buffer. The pH was 
maintained at Z2-7.4 by adding Hepes buffer or sodium bicarbonate when 
necessary. In cell attachment assays the peptides were dissolved in the same 
medium except that serum was omitted. Peptide/media preparations were 
made fresh for each experiment. 
Cell Attachment to Defined Substrates 
Cell attachment assays were done as described (Ruoslahti et al., 1982). In 
some experiments, the cells used for the attachment assays were radiota- 
beled with [l~Clthymidine  (ICN Radiochemicals, lrvine, CA; see below) 
and the cell-associated radioactivity was used to quantitate the attached 
cells. The assays were performed in triplicate. 
Cell Invasion Assays 
lnvasiveness of tumor cells was determined using the Membrane Invasion 
Culture System (MICS, Gehlsen et al., 1984; Gehlsen and Hendrix, 1986; 
Hendrix et al., 1985b) which is a modification of the amnion invasion assay 
described by Liotta et al. (1980).  Briefly,  cells (5  ￿  104 to 1 ￿  105) were 
radiolabeled with 0.25  ~tCi/ml  ~4C-thymidine or 0.30 ~tCi/ml  [125I]deoxy- 
uridine ([t25I]Udr),  both from New England Nuclear (Boston, MA),  for 
48 h in medium containing 2% serum and then seeded into the upper com- 
partment of the MICS chambers. After a preattachment incubation period 
at 37~  in a 7% CO~-air  atmosphere and at 24-h intervals thereafter, me- 
dium in both the upper and lower compartments of the chambes was re- 
placed with fresh, peptide-containing medium. At specific time intervals af- 
ter the addition of peptides, medium from the upper and lower chambers 
was removed, the membranes were washed with fresh medium, and the 
medium and wash fractions were centrifuged and the number of cells in the 
cell pellets was determined by counting the cell-associated radioactivity by 
liquid scintillation or in a gamma counter. The total  number of cells that 
had passed through the membrane was derived by adding the lower chamber 
value to those from the previous samplings. In several experiments, un- 
labeled cells were used and the cells were counted in a hemocytometer. In 
addition, the cell-associated radioactivity in the amnion tissue was also de- 
termined. The amnion was treated in tissue solubilizer (Amersham Corp., 
Arlington Heights, IL) before counting radioactivity. 
Microscopy 
The localization of cells during invasion was determined using A375M cells 
labeled with the lipophilic dye, 1,1 '-dioctadecyl-3,3,3',3'-tetramethylinado- 
carbocyanine perchlorate (DiI;  Molecular Probes, Inc., Eugene, OR), as 
described (Honig and Howe, 1986). Dil was dissolved in 100% ethanol (2 
mg/ml) and added to cells in culture medium at a final ethanol concentration 
of 3%  for 12-24 h. Cells were then washed with PBS followed by fresh 
medium before seeding into MICS chambers. After a 72-h incubation period 
the membanes were washed thee times with PBS, fixed in 3.75% parafor- 
maldehyde and frozen for cryostat sectioning. Membrane preparations were 
then viewed and photographed using a Nikon Diaphot-TMD inverted micro- 
scope equipped with fluorescence optics. 
Results 
Effects of  RGD-containing Peptides on 
Melanoma Cell Invasion 
We  have  used  RGD-containing  cell  adhesion  peptides  to 
study the role of cell adhesion receptors in the penetration 
of tumor cells through amniotic membrane tissue. As previ- 
ously noted (Hendrix et al.,  1985a),  the metastatic  mela- 
noma cell lines, A375M and A375P,  were each able to tra- 
verse the human amniotic membrane in the MICS invasion 
assay with an increasing number of cells reaching the lower 
chamber  with  time.  The  RuGli  glioblastoma  cells  also 
penetrated the membrane. 7-9% of the A375M cells, 3-5% 
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Figure L The effect of RGD-con- 
taining peptides on tumor cell in- 
vasion.  A375M  melanoma  (A) 
and RuGli glioblastoma (B) cells 
were  tested  in  MICS  invasion 
chambers as described. The num- 
bers of cells that had accumulated 
to  the  lower  chamber  compart- 
ment at 72 h  were used to calcu- 
late  invasion.  The  uninhibited 
control values  were set at  100% 
with the data  derived from nine 
observations for each point.  The 
mean +SD is shown as a percent- 
age of tumor cell invasion relative 
to the controls. 
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Figure 2.  The effects of two selective  synthetic  RGD-contalning 
peptides  on  A375M  melanoma  cell  invasion.  GRGESP  (o); 
GRGD, D-Ser, P ([]); or the cyclic RGD peptide  (A) were added to 
MICS chambers and their effects on cell  invasion was assayed as 
described in the text and the legend of Fig.  1. 
the membranes traversed the amnion in 72 h. A  marked de- 
crease in the invasion was seen in the presence of RGD-con- 
taining peptides with all  three cell lines.  This inhibition of 
invasion was apparent at all time points analyzed, but it was 
greatest at 72 h (data not shown). For this reason, this time 
point was used in the subsequent experiments.  Results from 
such an experiment in which several  RGD-containing pep- 
tides and a control peptide were tested with the A375M and 
RuGli cells are shown in Fig.  1. The data show that each of 
the RGD-containing peptides inhibited invasion, whereas the 
control  peptide  in  which  the  aspartic  acid  has  been  sub- 
stituted with glutamic acid rendering it inactive in cell attach- 
ment assays (Pierschbacher and Ruoslahti,  1984b) was with- 
out effect. A hexapeptide with a D-alanine in the place of the 
second glycine (Pierschbacher and Ruoslahti,  1987) was also 
inactive (results  not shown). 
Peptide Specificity in the Inhibition of Invasion 
The results shown in Fig.  1 suggested that RGD-containing 
adhesion proteins and their receptors play a role in tumor cell 
invasion.  We next attempted  to determine  which adhesion 
protein(s) and receptor(s) might be important in this invasion 
using peptides  that preferentially  inhibit cell attachment to 
individual adhesion proteins. The effects of the various pep- 
tides that are shown in Fig.  1 are informative in this regard. 
The  prototype,  fibronectin-derived  GRGDSP  peptide  in- 
hibits the binding of the fibronectin and vitronectin receptors 
to their ligands (Pytela et al.,  1985a,b). The GRGDNP pep- 
tide in which an asparagine follows the RGD sequence has 
a  similar  specificity but  is  about  sixfold more active than 
the  prototype  peptide  at  inhibiting  attachment  of cells  to 
fibronectin  compared  with  vitronectin  (Pierschbacher  and 
Ruoslahti,  1987).  The GRGDTP peptide which, unlike the 
other peptides, inhibits the attachment of cells to type I colla- 
gen, as well as to fibronectin and vitronectin (Dedhar et al., 
1987), was consistently more active in the invasion assay than 
GRGDSP, suggesting that type I collagen may also play some 
role in the invasion process. 
To distinguish between the involvement of the fibronectin 
and vitronectin receptors we used two peptides that inhibit 
only one but not the other of these receptors. A cyclic RGD 
peptide inhibits attachment predominantly to vitronectin and 
not to fibronectin, whereas a peptide in which a o-serine res- 
idue  replaces  the  L-serine  has  the  opposite  specificity 
(Pierschbacher and Ruoslahti,  1987). As shown in Fig. 2, the 
cyclic peptide was an inefficient inhibitor of invasion, where- 
as the D-serine peptide was as active as the standard peptide 
GRGDSE 
Effects of  Peptides on Tumor Cell Attachment 
The effects of the peptides used in the experiments described 
above on cell  attachment  had been  studied  with cell  lines 
different from the ones used here. Since a mouse melanoma 
cell line has been found to attach to fibronectin through a site 
different  from  the  RGD  site  (Humphries  et  al.,  1986b; 
McCarthy et al.,  1986),  it was necessary to determine the 
effects of the  peptides  on the  attachment  of the  A375 and 
RuGli cells.  Moreover,  since the amniotic basement mem- 
brane contains laminin and type IV collagen (Liotta et al., 
1983)  it was also  important to know whether the peptides 
would affect attachment of the tumor cells to these proteins. 
Earlier results have indicated that the RGD-containing pep- 
tides tested  so far do not inhibit the attachment of various 
types of cells to laminin or type IV collagen (Aumailley and 
Timpl,  1986; Goodman et al.,  1987; Graf et al.,  1987),  but 
a  laminin  receptor  recognizing  RGD  has  been  described 
(Horwitz et al.,  1985).  The RGD peptides inhibited the at- 
tachment  of  the  A375  and  RuGli  cells  to  fibronectin, 
vitronectin and type I collagen with the same specificities as 
has been previously found with other cells  (Dedhar et al., 
1987, Pierschbacher and Ruoslahti  1984a,b,  1987).  Little or 
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Figure 3. The effects of  GRGDTP on A375M cell attachment to vari- 
ous extracellular  matrix  proteins.  A375M cells were seeded on ei- 
ther fibronectin  (FN), vitronectin (VN), laminin  (LM), collagen 
type IV, or collagen type I in the presence of the GRGDTP peptide. 
About 90% of the cells attached to the wells coated with fibronectin 
and vitronectin in the absence of the peptide, while '~80% attached 
to laminin,  70% to type IV collagen  and 46% to type I collagen. 
These values were designated at 100%. Inhibition of  cell attachment 
is shown as a percentage  of cells attached  relative to controls.  All 
assays were done in triplicate  as described in the text. 
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Figure 4.  Distribution  of tumor cells  within  the invasion  system. 
A375M cells were allowed to attach to the amniotic membrane in 
MICS chambers for 4 h before the addition  of either  1 mg/ml  of 
GRGESP 02) or GRGDTP ([]).  The invasion was allowed to pro- 
ceed for 72 h and the number of cells  located  in either the upper 
well, within or adherent to the basement membrane portion of the 
amniotic membrane or in the lower wells was determined.  The bar 
diagram represents  the number of cell  in each compartment as a 
percentage  of the original number of cells  seeded,  +SD. 
no inhibition  of attachment to type IV collagen or laminin 
was seen with any of the peptides. The results for the A375M 
melanoma cells and the GRGDTP peptide were representa- 
tive and are shown in Fig.  3. 
The lack of inhibition of the laminin and type IV collagen 
induced  cell  attachment  by  the  RGD-containing  peptides 
suggested that the attachment of the tumor cells to the am- 
niotic  basement  membrane  should  not  be  affected  by  the 
RGD-containing peptides. When this was tested, partial inhi- 
bition of cell attachment was seen when the tumor cells were 
seeded on the amniotic basement membrane in the presence 
of the  RGD-containing peptides  (result  not  shown).  How- 
ever, if the cells were first allowed to attach to the membrane 
during a preincubation period, as was the case with the inva- 
sion assays, the number of  unattached cells floating in the up- 
per chamber after subsequent  incubation with the peptides 
for 1-72 h was not significantly different from that in control 
incubations. The results for the 4-h preincubation are shown 
in Fig. 4. The 10% of nonadherent cells with or without the 
peptides may have been detached due to degradation of the 
amniotic  membrane by the tumor ceils,  cell  death,  or cell 
proliferation.  Unlike the results on the amniotic membrane, 
cells plated similarly on fibronectin or type I collagen sub- 
strate could be completely detached with the peptides (result 
not shown, see Hayman et al.,  1985a). These results indicate 
that the effect of the RGD peptides on the tumor cell invasion 
is not likely to be due to inhibition of the initial cell attach- 
ment to the amnion, but rather appears to result from inhibi- 
tion of subsequent invasion steps involving fibronectin, and 
collagen  or  other  as  yet  unidentified  molecules.  A  fur- 
ther control experiment showed that the soluble fibronectin 
added to the assay in the fetal bovine serum which was part 
of the culture  medium  is  not a  factor in the assay.  The in- 
Figure 5. Visualization of invading tumor cells within the amniotic 
membrane.  The A375M  cells  were  labeled  with  the  fluorescent 
lipophilic  dye, DiI, and allowed to invade the amniotic membrane 
for 72 h in the presence of either GRGESP (A) or GRGDTP (B), 
as described for the previous invasion assays. The visualization  of 
cell  location during the  invasion  period was then determined  by 
fluorescent  microscopic  examination  of the  sectioned  amniotic 
membrane.  Basement  membrane  surface  (upper arrow) and  the 
lower stromal  surface (lower  arrow) of the amniotic membrane are 
shown. 
volvement of soluble fibronectin was excluded by seeding the 
A375M cells into the invasion chambers in the presence of 
50 pg/ml of fibronectin.  This addition,  which represents  a 
10-fold increase in fibronectin concentration above what is 
present in 10%  fetal bovine serum (Hayman et al.,  1985b), 
had no effect on the invasion or on the ability of the peptides 
to inhibit it (result  not shown). 
Visualization of CeU Location during Invasion 
To visualize  the  invading cells  in the amniotic membrane, 
fluorescently labeled cells were seeded onto amniotic mem- 
branes  in  MICs  chambers.  The  labeled  cells  invaded  as 
efficiently as unlabeled  cells and the GRGDTP peptide  in- 
hibited this invasion.  Cross sections of the amniotic mem- 
branes were examined by fluorescent light microscopy to lo- 
cate  the  cells.  In  experiments  performed  with  a  control 
peptide  (GRGESP),  cells  at  various  stages  of  migration 
throughout the amnion were observed (Fig.  5 A),  whereas 
examination of over 100 sections from experiments with the 
GRGDTP  peptide  revealed  no  cells  within  the  amnion 
stroma.  In this case the cells were located at the basement 
membrane surface or directly beneath  the basement mem- 
brane  (Fig.  5  B). 
Discussion 
In this paper,  we report that RGD-containing synthetic pep- 
tides can inhibit in vitro tumor cell invasion through a human 
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tion-dependent, nontoxic, and correlates with the ability of 
the peptides to interact with matrix adhesion receptors. The 
specificity of the effect was  shown by the fact that control 
peptides had little or no effect on invasion. 
For the tumor cells to invade through the amniotic mem- 
brane in our system, they must go through a series of steps 
one or several of which may be inhibited by the peptides. 
First,  the cells have to attach to the basement membrane 
which in our experiments was denuded of cells and oriented 
toward the seeded tumor cells. The basement membrane at- 
tachment is likely to be an important step in this in vitro inva- 
sion system, as well as in vivo (Liotta et al., 1983, 1986). The 
RGD-containing peptides showed only minimal inhibition of 
the attachment of the tumor cells to the basement membrane 
and had no detaching effect after the cells had already at- 
tached to it.  Therefore, because the  invasion experiments 
reported here were performed by adding the peptides after 
a  2-4-h  preattachment period,  we  can conclude that  the 
mode of action of  the peptides was not inhibition of  the initial 
cell attachment. This is in agreement with the fact that the 
peptides did not substantially inhibit the attachment of the tu- 
mor cells to laminin or type IV collagen which are the two 
main adhesive proteins in basement membranes. In addition, 
the localization of fluorescently labeled tumor cells showed 
that the cells in the presence of the RGD-containing peptides 
remain attached at the surface of the amniotic membrane or 
penetrate only slightly into the basement membrane. 
The localization of the cells that were prevented by the 
RGD-containing peptides from invading suggests that the in- 
vasion step inhibited is the penetration of the cells into and 
through the stromal portion of  the amniotic membrane which 
is  about four-fifths of the thickness  of the  membrane.  In 
agreement with this is that stromal extracellular matrix con- 
tains the adhesive proteins fibronectin and type I collagen 
(Liotta et al., 1983), cell attachment to which is inhibited by 
the RGD-containing peptides we have used. Since only those 
peptides among a group of closely related peptides that can 
inhibit cell attachment also inhibit invasion, the cell surface 
receptors recognizing RGD sequences in adhesive proteins 
are likely to be involved in the invasion process. 
The GRGDSP peptide  from the  fibronectin cell-attach- 
ment site inhibits the attachment of cells to fibronectin and 
vitronectin but not to collagen (Dedhar et al., 1987; Hayman 
et al.,  1985a). That this peptide inhibits invasion suggested 
a role for the fibronectin and/or vitronectin receptors. It also 
suggested that collagen receptors would not play a substantial 
role in the invasion. However, an indication of some involve- 
ment of type I collagen receptors was obtained with the pep- 
tide,  GRGDTP, which  inhibits not only the attachment of 
cells to fibronectin and vitronectin, but also to type I collagen 
(Dedhar et al., 1987). This peptide was consistently the most 
active inhibitor among the peptides tested in the invasion as- 
say. Thus, collagen receptors may also play a role in cell in- 
vasion. Two of the RGD peptides we have developed recently 
(Pierschbacher and Ruoslahti,  1987) allowed us to evaluate 
the relative contribution of the fibronectin and vitronectin 
receptors to the invasion process. 
Introduction of a o-serine into the serine position of the 
standard GRGDSP peptide yields a peptide that inhibits the 
function of the fibronectin receptor but not of the vitronectin 
receptor. That this peptide had an essentially unaltered activ- 
ity relative to the standard GRGDSP peptide in the invasion 
assay  suggests  that,  of the  two  receptors,  the  vitronectin 
receptor does not play a substantial role in the invasion pro- 
cess. The low activity of the cyclic RGD-containing peptide 
which inhibits the function of the vitronectin receptor but not 
the fibronectin receptor, supports this conclusion. Perhaps 
the amniotic membrane contains an insufficient amount of 
vitronectin,  or other ligands  that the  vitronectin receptor 
could recognize, for this receptor to play a role in the inva- 
sion. On the other hand, it is possible that other, as yet un- 
known RGD-directed receptors might also be important in 
addition to the fibronectin and collagen receptors. 
The results with the cyclic peptide also allowed another 
important conclusion. Even though the tumor cells have the 
vitronectin receptor which the cyclic peptide binds to, this 
peptide did not inhibit invasion.  This shows  that mere oc- 
cupancy of an adhesion receptor at the cell surface does not 
cause inhibition of invasion. The inhibition of invasion by the 
peptides that can interfere with the  likely cell attachment 
phenomena in the amniotic stroma strongly suggests that at- 
tachment of cells to the stromal matrix is needed for invasion 
and tends to exclude alternative possibilities.  For instance, 
the ability of tumor cells to degrade extracellular matrices 
is important in invasion (Liotta et al.,  1986; Mignatti et al., 
1986) and cell surface proteins are closely associated with 
adhesion  sites  (Chen  et al.,  1987, P611iinen et al.,  1987). 
Therefore, the peptides could conceivably inhibit invasion by 
inhibiting  proteolysis.  However,  the  peptide  specificity 
favors the explanation that the peptides deny the cells the 
traction they would need to derive from matrix adhesion to 
move through tissue. 
Humphries et al. (1986a)  have recently found that RGD- 
containing peptides when injected together with melanoma 
cells into mice can inhibit the colonization of the lungs by 
the tumor cells. Although there is evidence that the entry of 
blood borne cells into tissues depends on RGD interactions 
(Savagner et al.,  1986), we think il unlikely that the inhibi- 
tory effect on invasion we have demonstrated would be the 
basis of the effect on experimental metastasis found by Hum- 
phries et al.,  1986a.  The reason for this is that the peptides 
have an  in vivo half-life of only a  few minutes  (Piersch- 
bacher, M.  D., and P.  M.  Cardarelli, unpublished results), 
whereas invasion into tissues is likely to take much longer. 
Perhaps the peptides in the experimental metastasis model 
inhibit the initial stages of cell attachment to vascular en- 
dothelial cells or to the underlying subendothelial matrix, 
which may contain more fibronectin and be somewhat differ- 
ent in structure and composition than the amniotic basement 
membrane. 
It is commonly held that extracellular matrices are impor- 
tant for tumor cell attachment in their new, metastatic loca- 
tion, but in other ways these matrices have been viewed as 
barriers  to  tumor  cell  invasion  (Liotta,  1986;  Ruoslahti, 
1984). The barrier concept may be correct in the special case 
of basement membranes, but an important suggestion from 
our present work is that at least the connective tissue matrix 
may be a  facilitator of tumor invasion,  not a barrier.  The 
RGD-containing peptides may become useful in counteract- 
ing the invasion of tumor cells through such tissues, leading 
to possible future therapeutic roles for these peptides. 
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